Gothenburg, Sweden, August 25, 2016 – The nomination committee of Immunicum AB (publ) proposes that Steven Glazer, Charlotte Edenius and Kerstin Valinder Strinnholm be elected as new Board members at the Annual General Meeting on October 26, 2016.
“Immunicum is now entering a new exciting phase, with more focus on business and licensing activities. If the nominations are accepted at the annual general meeting, Steven, Charlotte and Kerstin bring valuable expertise in these areas”, says Agneta Edberg, Chairman of the Board.
Steven Glazer is an experienced healthcare and biotech executive. He has extensive and broad therapeutic area experience including haematology, oncology, haemophiia, HIV, diabetes, allergic and cardiovascular disease from pharmaceutical and biotechnology companies in Europe and United States. He has a track record of successful planning and implementation of development, regulatory and corporate strategies, project and trial plans. Dr Glazer currently holds the position of Chief Medical Officer at Hansa Medical AB and served as Senior Vice President Development at BioInvent AB, Vice President Development at Zealand Pharma and Medical Director at Novo Nordisk. Steven holds a Doctor of Medicine from the University of Copenhagen and trained in Internal Medicine.
Charlotte Edenius has extensive experience from leading positions in pharmaceutical and biotech companies, including drug discovery and development, regulatory affairs and marketing. She has previously served as Executive Vice President, R&D, Medivir AB; Senior Vice President R&D, Orexo AB; Vice President Research, Biolipox; and in various positions within AstraZeneca Clinical R&D. Charlotte is presently Director of the Boards at Kancera AB, Aptahem AB and SynAct Pharma AB. She holds an MD and PhD from the Karolinska Institutet, Stockholm.
Kerstin Valinder Strinnholm is a Business Development advisor in the pharma/biotech field with a degree from the School of Journalism at the University of Gothenburg. Kerstin has over 30 years of international experience in sales, marketing and business development from senior positions at Astra/AstraZeneca and Nycomed Takeda. Other board positions include Camurus AB, Corline Biomedical AB and Cavastor AB.
Bengt Furberg declines re-election.
For more information, please contact:
Agneta Edberg, Chairman of the Board, Immunicum
Ph: +46 709 10 42 22
Evert Carlsson, Chairman of the nomination committee, Immunicum
Ph: +46 705 90 82 24
About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company’s most advanced product – INTUVAX® against kidney cancer – has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST). Immunicum is listed on First North Premier.
The Company’s Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31
The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company’s contact person on August 25, 2016 at 08.30 CET